ALS
Created:   10/20/2011
Contains:  48 items

Creator: Olga Rukovets
Duration: 7:34
Neurology Today 
In a poster presented at the AAN annual meeting last March, researchers reported that three preoperative tests combined with clinical judgment are helpful in predicting diaphragm excitability in amyotrophic lateral sclerosis (ALS) patients. Here, author Robert Baloh, MD, director of neuromuscular medicine in the department of neurology at Cedars-Sinai, talks about the currently available data on the Diaphragm Pacing System in ALS patients and what research still needs to be done.
Creator: Neurology Today
Duration: 3:45
Journal: Neurology Today
From the AAN Annual Meeting: Is dexpramipexole safe and effective for patients with ALS? In a video interview, Neurology Today’s Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the key clinical takeaways from the latest analysis of data on the trial involving dexpramipexole for ALS.
Creator: Neurology Today
Duration: 4:58
Journal: Neurology Today May 16, 2013, Volume 13, Issue 10;
In a study presented at the AAN annual meeting last March, researchers reported that three preoperative tests combined with clinical judgment are helpful in predicting diaphragm excitability in amyotrophic lateral sclerosis (ALS) patients. In a video interview, Neurology Today’s Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the implications of these findings for ALS experts and patients.
Creator: Neurology Today
Duration: 2:43
Journal: Neurology Today
An antisense oligonucleotide tailored to target part of the messenger RNA of superoxide dismutase 1 (SOD1) was found safe in a small trial involving 21 patients with amyotrophic lateral sclerosis, but the investigators contend they need to do more long-term experiments in animal models of ALS before moving forward. Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD discuss the promise and challenges ahead for antisense oligonucleotide therapy for ALS.